Meningitis, a life-threatening condition affecting millions worldwide, continues to burden the global healthcare system severely. With over 1.2 million cases expected to be registered annually, bacterial meningitis remains a significant cause of morbidity and mortality in several countries. The Centers for Disease Control and Prevention (CDC) reports that bacterial meningitis has a fatality rate of up to 70% if left untreated.
For More Industry Insight Read : https://www.fairfieldmarketresearch.com/report/meningitis-vaccines-market
The grave consequences of bacterial meningitis, especially the risk of permanent neurological sequelae, have triggered a surge in demand for meningococcal vaccines. Increasing awareness about the disease's impact and prevalence, especially among children up to one year of age, has led several countries to include meningococcal vaccines in their national immunization programs.
The Menace of Meningitis in Africa
The World Health Organization has highlighted the disproportionate prevalence of bacterial meningitis in sub-Saharan Africa, known as the meningitis belt. Approximately 400 million people living in 26 different countries across the belt are affected by bacterial meningitis every year, posing a significant concern for the region's health infrastructure and the global healthcare system. The critical need for adequate immunization against the disease has spurred the growth of the meningitis vaccine market.
Meningitis Research Foundation (MRF) Driving Progress
Research studies focusing on bacterial meningitis's geographic and epidemiological characteristics have been instrumental in advancing the meningitis vaccine market. The Meningitis Research Foundation (MRF) has taken a global vision to defeat meningitis by 2030. Since 1989, MRF has awarded nearly 161 research grants and invested approximately USD 28 million in scientific research around bacterial meningitis. Such initiatives have raised awareness and accelerated vaccine development and commercialization.
Challenges in the Market and the Impact of COVID-19
Despite progress, the meningitis vaccines market faces challenges, with rates of meningitis vaccines witnessing a lesser fall compared to other vaccine-preventable diseases. Bacterial meningitis's inclusion under global health priorities has yet to be fully realized, hindering the market's long-term growth.
The global COVID-19 outbreak has highlighted the importance of vaccination, indirectly benefiting the meningitis vaccine market. Strengthened healthcare infrastructure and a favorable vaccine supply scenario have increased demand for significant vaccination programs, including meningococcal vaccines.
Meeting Growing Demand and Key Players
Manufacturers are introducing new products to address the rising demand for meningococcal vaccines. The MenACWY Conjugate Vaccine Market is expected to expand significantly, especially in countries across the meningitis belt. Manufacturers from China and India are leading the way with multiple products in their pipelines, eyeing the global demand.
Key players in the procurement and production of meningococcal vaccines include the Serum Institute of India (SII), Chongqing Zhifei, GlaxoSmithKline Biologicals, Sanofi Pasteur, Vacsera, Pfizer, Nuron Biotech, China National Biotech Group, Bio-Manguinhos/Fiocruz, Hualan Biological Bacterin Co., Ltd, and Beijing Institute of Biological Products Co., Ltd.
Conclusion
Bacterial meningitis seriously threatens global health with its significant morbidity and mortality rates. The rise in demand for meningococcal vaccines and the increasing inclusion of vaccines in national immunization programs underscore the urgent need to address this health challenge. Organizations like the Meningitis Research Foundation (MRF) are crucial in driving research and awareness.
Read more :
